Finance

Beta
Lists
DNLI:NASDAQ
Denali Therapeutics Inc
$19.52
-3.08%
(-0.62) 1D
$19.55
+0.15% (+0.030)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNLI...
Open
$19.94
High
$19.94
Low
$19.24
Mkt. cap
3.10B
Avg. vol.
1.82M
Volume
2.19M
52-wk high
$23.77
52-wk low
$12.58
EPS
-$2.88
Beta
1.03
Shares outstanding
158.71M
No. of employees
507
Open
$19.94
High
$19.94
Low
$19.24
Mkt. cap
3.10B
Avg. vol.
1.82M
Volume
2.19M
52-wk high
$23.77
52-wk low
$12.58
EPS
-$2.88
Beta
1.03
Shares outstanding
158.71M
No. of employees
507
Analyst outlook
Analyst Ratings
Based on 13 analysts giving stock ratings to DNLI in the past 3 months
Strong Buy
Buy
13
Hold
0
Sell
0
12 month forecast
Based on 13 Wall Street analysts offering 12 month price targets for DNLI in the last 3 months.
Highest
Current $19.52
$42.00 (+115.16%)
Average
$35.50 (+81.86%)
Lowest
$23.00 (+17.83%)
News stories
From sources across the web
About Denali Therapeutics Inc
CEO-
Employees507
Founded2013
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitedenalitherapeutics.com
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.69 / -$0.71
+2.17%beat
Revenue / Est. (USD)
- / 2.32M
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
102.70M
101.95M
97.90M
103.85M
Cost of revenue
102.70M
101.95M
97.90M
103.85M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32.27M
35.48M
39.46M
33.51M
Operating expense
32.27M
35.48M
39.46M
33.51M
Total operating expenses
134.96M
137.43M
137.36M
137.36M
Operating income
-134.96M
-137.43M
-137.36M
-137.36M
Other non operating income
-
-
-
-
EBT including unusual items
-124.12M
-126.90M
-128.45M
-128.45M
EBT excluding unusual items
-124.12M
-126.90M
-130.09M
-129.71M
Income tax expense
-
-
102.00K
-
Effective tax rate
-
-
-0.08%
-
Other operating expenses
-
-
-
-
Net income
-124.12M
-126.90M
-128.55M
-128.45M
Net profit margin
-
-
-
-
Earnings per share
-0.72
-0.74
-0.73
-0.69
Interest and investment income
11.04M
10.73M
7.28M
7.83M
Interest expense
-200.00K
-200.00K
-
-179.00K
Net interest expenses
10.84M
10.53M
7.28M
7.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
-131.01M
-133.57M
-133.58M
-133.60M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer